Jesse Damsker, PhD.

Chief Operating Officer

Dr. Damsker has an extensive background in immunology and the regulation of inflammatory diseases.  He earned his doctorate at the George Washington University School of Medicine and completed a post-doctoral fellowship at the National Institutes of Health. In 2010, Dr. Damsker brought his immunological expertise to ReveraGen and spearheaded studies that characterized vamorolone’s anti-inflammatory properties using in vitro and in vivo model systems of acute and chronic inflammation.  Currently, he directs the preclinical research at ReveraGen including programs on additional indications for vamorolone and implementation of new programs. He also oversees many of the business operations on a day-to-day basis.